Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information


Life Sciences Fund V, 6/2010 $523M
Sixth Health-care Fund, 1/2014 $525M


One Boston Place
201 Washington Street, Suite 3900
Boston, MA, 02108
Foster City, USA
Metro Center
950 Tower Lane, Suite 1725
Foster City, CA, 94404
London, GBR
71 Kingsway
London, WC2B 6ST, GBR


Managing Partner
Managing Partner
Managing Partner
Managing Partner
Partner & CFO
Venture Partner
Show All People


SV Life Sciences

SV Life Sciences is a venture capital adviser and manager that makes selected investments in entrepreneurs and management teams.

SV Life Sciences provides finance to businesses at all stages of development and across the human life sciences sector. These sectors range from biotechnology & pharmaceuticals to medical devices & instruments, to healthcare information technology and services. SV Life Sciences currently advises or manages five funds with capital commitments of approximately $1.5 billion which primarily invest amounts of between $1m and $40m in North America and Europe, but will consider innovative investments in other regions. Our team of 34 professionals has a diverse, complimentary set of skills and experience that allow us to tailor a team to work with almost any life sciences business.

Recent Milestones


Company Date Round Size Participants
PanOptica 4/2014Series B$45M3
Thesan Pharmaceuticals 2/2014Series B$49M4
AqueSys 1/2014Series D$43.6M5
TopiVert 1/2014Venture Round£4.5M4
CSA Medical 12/2013Series C$16M7
Sutro Biopharma 12/2013Series D$26M6
Pulmocide 11/2013Series A£17M4
Catabasis Pharmaceuticals 11/2013Series B$32.4M5
Delenex Therapeutics 11/2013Series A$8M5
Affinium Pharmaceuticals 9/2013Debt$11.9M3
Arsanis 9/2013Series B$20M4
OncoEthix 7/2013Series B$19M4
CardioKinetix 3/2013Series E$23M6
Catabasis Pharmaceuticals 2/2013Venture Round$9M4
Ocular Therapeutix 1/2013Series D$23.8M4
Bicycle Therapeutics 12/2012Venture Round£3.75M5
Health Essentials 10/2012Venture Round2
ReShape Medical 10/2012Series C$15M3
Cibiem 10/2012Series A$10M2
Karus Therapeutics 9/2012Series B$7.6M4
Cyterix Pharmaceuticals 7/2012Venture Round$7.29M1
Sutro Biopharma 5/2012Series C$16.5M5
Adimab 4/2012Venture Round$14M3
AlloCure 4/2012Series B$25M3
WellNow Urgent Care Holdings 2/2012Venture Round$35M3
CSA Medical 12/2011Series B$20.5M4
Catabasis Pharmaceuticals 12/2011Series A$8M4
TopiVert 12/2011Venture Round£8M2
AcuFocus 11/2011Series F$65M5
Rempex Pharmaceuticals 11/2011Series B$67.5M5
Imagen Biotech 10/2011Series A$40M3
CardioKinetix 9/2011Series E$44M4
Affinium Pharmaceuticals 8/2011Venture Round$15M3
KalVista Pharmaceuticals 8/2011Series A£8M2
Entellus Medical 8/2011Series E$35M5
Vantia Therapeutics 7/2011Series B$6.5M3
Cyterix Pharmaceuticals 6/2011Series A$9.2M2
Delenex Therapeutics 5/2011Series A$19.3M6
Arsanis 2/2011Series A$10M3
CardioFocus 2/2011Series C$30.6M9
PanOptica 1/2011Series A$30M2
Sutro Biopharma 11/2010Series C$36.5M5
Delenex Therapeutics 11/2010Series A$14M4
Convergence Pharmaceuticals 10/2010Series A$35.4M3
Good Start Genetics 9/2010Series A$18M3
Altura Medical 6/2010Series A$20M3
AqueSys 6/2010Series C$35M5
Logical Therapeutics 5/2010Series C$16.9M3
Catabasis Pharmaceuticals 4/2010Series A$39M4
Juvaris BioTherapeutics 4/2010Series B$12.5M2
Juvaris BioTherapeutics 1/2010Series B$25M2
Adimab 1/2010Series D$8.2M5
TransEnterix 1/2010Series B$55M6
Ophthotech 12/2009Series B$30M4
Oxagen 11/2009Series C$26.7M9
Entellus Medical 11/2009Series D$30M3
Lux Biosciences 10/2009Series B$50M4
ValenTx 10/2009Series B$20.3M6
Cadent 8/2009Venture Round$19.3M5
Ocular Therapeutix 6/2009Series C$15M3
Sadra Medical 5/2009Series C$30M7
Sutro Biopharma 3/2009Series B$15M2
NKT Therapeutics 3/2009Series A$8M2
LensX Lasers 3/2009Series B$22.4M3
ReShape Medical 2/2009Series B$20M3
Adimab 11/2008Series C$4M4
ESBATech 8/2008Series B$22M7
EBR Systems 6/2008Series C$35M5
Entellus Medical 5/2008Series C$15M3
Sutro Biopharma 12/2007Series B$21M2
Sutro Biopharma 10/2007Venture Round$305k2
Adimab 9/2007Series A$5.9M2
ReShape Medical 8/2007Series A$3M2
Entellus Medical 5/2007Series B$9M2
NeoVista 12/2006Series C$41M6
Neurotech 11/2006Series B$35M12
Sadra Medical 10/2006Series B$19M5
NeoVista 9/2006Series B$26M4
ESBATech 8/2006Series B$41M7
Entellus Medical 4/2006Series A$3M2
Sutro Biopharma 1/2006Series A$1M1
Mpex Pharmaceuticals 8/2005Series B$32M6



  1. SV Life Sciences flush with venture cash, bullish on exit deals Read more: SV Life Sciences flush with venture cash, bullish on exit deals ( [edit]
  2. The Daily Startup: SV Life Sciences to Boost Late-Stage Deals for $525M Fund VI ( [edit]
  3. PanOptica Closes Up To $45M in Series B Funding ( [edit]
  4. Thesan Pharmaceuticals Closes $49M Series B Financing ( [edit]
  5. AqueSys Secures $43.6M in Series D Financing ( [edit]
  6. TopiVert Raises Follow-on Funding ( [edit]
  7. CSA Medical Closes $16M Series C Financing ( [edit]
  8. Sutro Biopharma Secures $26M in Series D Financing ( [edit]
  9. Pulmocide Raises £17M in Series A Funding ( [edit]
  10. Catabasis Pharmaceuticals Completes $32.4M Series B Financing ( [edit]
  11. Delenex Therapeutics closes CHF 7.3 Million Series A3 Financing ( [edit]
  12. Affinium Pharmaceuticals raises $12 million in debt financing ( [edit]
  13. Arsanis, Inc. Closes $20 Million Series B Financing ( [edit]
  14. OncoEthix Closes 19 Million Series B Financing ( [edit]
  16. Catabasis raises $9M for PhII-ready drug development program ( [edit]
  17. Ocular Therapeutix, Inc. Closes on $23.8 Million Series D Extension ( [edit]
  18. Bicycle Therapeutics Raises £3.75M in Funding ( [edit]
  19. Health Essentials Receives Growth Capital Investment ( [edit]
  20. Obesity-Device Maker ReShape Medical Raises More Than $15M of $20M Series C ( [edit]
  21. Cibiem Raises $10M in Series A Financing ( [edit]
  22. Karus Thera Picks Up $7.6M to Develop Two Preclinical Compounds ( [edit]
  23. VC Funding: Q3 2012 source [edit]
  24. Sutro Closes $16.5 Million Second Tranche of Series C Financing ( [edit]
  25. Google contributes to $14M round for fast-growing Adimab ( [edit]
  26. AlloCure raises $25M round for kidney disease trial ( [edit]
  27. WellNow Urgent Care Launches with $35M ( [edit]
  28. CSA Medical Raises $20.5M in Series B Funding ( [edit]
  29. Catabasis Pharmaceuticals Announces $8 Million Series A Extension Financing ( [edit]
  30. TopiVert Raises £8M ( [edit]
  31. AcuFocus Closes $65M Financing ( [edit]
  32. Rempex Announces Series B Financing of up to $67.5 Million ( [edit]
  33. Imagen Biotech Secures Up to $40 Million to Advance Ophthalmology Therapies ( [edit]
  34. CardioKinetix Raises $44M in Series E Financing ( [edit]
  35. Affinium Pharmaceuticals Announces the Closing of $15 Million Financing ( [edit]
  36. KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema ( [edit]
  37. Entellus Medical Completes $35M Funding Round ( [edit]
  38. Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds ( [edit]
  39. Cyterix Pharmaceutics Raises $9.2M in Series A Financing ( [edit]
  40. Delenex Therapeutics Raises $19.3M ( [edit]
  41. Arsanis closes Series A financing for $10 million ( [edit]
  42. CardioFocus, Inc. Raises $30.6 Million in Private Financing ( [edit]
  43. PanOptica Raises $30m in Series A Financing ( [edit]
  44. Sutro Biopharma Secures $36.5M in Series C Financing ( [edit]
  45. Delenex Therapeutics Closes CHF13.5M Series A Venture Capital Financing Round ( [edit]
  46. Convergence Pharmaceuticals Raises $35.4M in Series A Financing ( [edit]
  47. Good Start Genetics, Inc. Raises $18 Million to Develop and Launch Sequencing‐Based Pre‐Pregnancy Genetic Screening Test ( [edit]
  48. Altura Medical, Inc.: Series A $20M ( [edit]
  49. AqueSys, Inc.: Series C $35M ( [edit]
  50. Logical Therapeutics closes $16.9M round for NSAID program ( [edit]
  51. Catabasis lands $39M Series A for diabetes programs ( [edit]
  52. Juvaris BioTherapeutics, Inc.: Series B $12.5M ( [edit]
  53. Juvaris BioTherapeutics Completes Second Close on $25M Series B Financing ( [edit]
  54. Adimab, Inc.: Series D $8.2M ( [edit]
  55. TransEnterix, Inc.: Series B $55M ( [edit]
  56. Ophthotech nabs $30M round to fund AMD trial ( [edit]
  57. Oxagen rounds up $26.7M in VC ( [edit]
  58. MorningStar ( [edit]
  59. Lux Biosciences scores $50M Series B for eye cure ( [edit]
  60. ValenTx, Inc.: Series B $20.3M ( [edit]
  61. SEC ( [edit]
  62. I-Therapeutix, Inc.: Series C $15M ( [edit]
  63. Sadra Medical, Inc.: Series C $30M ( [edit]
  64. Sutro Biopharma lands $15M with protein production ( [edit]
  65. NKT Therapeutics launches with $8M ( [edit]
  66. LensX Lasers nabs $22M for eye surgery lasers ( [edit]
  67. ReShape beefs up with $20M to bust fat ( [edit]
  68. Adimab, Inc. Announces Series C Financing ( [edit]
  69. ESBATech rounds up $22M in second round ( [edit]
  70. Capital Funding Report [edit]
  71. Split Rock Partners ( [edit]
  72. Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing Daniel S. Gold, PhD, Joins as Chief Executive Officer ( [edit]
  73. EDGAR [edit]
  74. SEC D ( [edit]
  75. ReShape Medical Secures $3 Million in Series A Financing ( [edit]
  76. Split Rock Partners ( [edit]
  77. NeoVista, a co. targeting age-related macular degeneration, raises $41M ( [edit]
  78. Neurotechâ„¢, Inc. Completes $35 Million Private Equity Financing ( [edit]
  79. Sadra Medical Raises $19 Million In Series B Financing ( [edit]
  80. NeoVista, a radiation treatment device maker, to raise $26M ( [edit]
  81. ESBATech Closes USD 41M Series B Venture Financing ( [edit]
  82. Split Rock Partners ( [edit]
  83. EDGAR [edit]
  84. Mpex Pharmaceuticals Closes $32 Million Series B Financing ( [edit]
Edit This Page
Last Edited 4/15/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy